Skip to main content

03.01.2024 | original article

Association of physical activity with MAFLD/MASLD and LF among adults in NHANES, 2017–2020

verfasst von: Minhua Li

Erschienen in: Wiener klinische Wochenschrift

Einloggen, um Zugang zu erhalten

Summary

Objectives

To investigate the correlations between physical activity (PA) and metabolic associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD) within a substantial population-based survey, and to examine the association between PA and liver fibrosis (LF).

Methods

Data from the 2017–2020 NHANES cycle were utilized in this study. PA was divided into four types: leisure-time PA (LTPA), transportation-related PA (TPA), occupational PA (OPA) and total time PA (total PA, which is composed of OPA, TPA and LTPA). Weighted logistic regression models were performed to analyze the associations between PA and MAFLD/MASLD and LF. Mediation analysis was used to explore whether LTPA completely mediated the statistically significant relationship between total PA and MAFLD/MASLD or LF.

Results

The study encompassed a sample size of 5897 participants aged 20 years and above, among the total participants, 2568 individuals with MAFLD and 2588 individuals with MASLD. There was no statistically significant correlation observed between OPA/TPA and MAFLD/MASLD and LF; however, active LTPA demonstrated an inverse association with MAFLD/MASLD (OR: 0.548; 95% CI: 0.458, 0.656/OR: 0.543; 95% CI: 0.453, 0.650), as well as a negative correlation with significant/advanced LF (OR: 0.457; 95% CI: 0.334,0.625/OR: 0.427; 95% CI: 0.295,0.619). There was also a significant inverse association between total PA and MAFLD/MASLD or LF, but this association was carried by the difference in LTPA.

Conclusion

Participation in active LTPA is associated with a reduced likelihood of MAFLD/MASLD and LF, while neither OPA nor TPA can replace these effects of LTPA.
Literatur
1.
Zurück zum Zitat Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–98. May.CrossRefPubMed Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–98. May.CrossRefPubMed
2.
Zurück zum Zitat Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75:454–61.CrossRefPubMed Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75:454–61.CrossRefPubMed
3.
Zurück zum Zitat Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;18;362:k2817. Jul.CrossRef Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;18;362:k2817. Jul.CrossRef
5.
Zurück zum Zitat Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8:1844–50.CrossRef Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8:1844–50.CrossRef
6.
Zurück zum Zitat Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5.CrossRefPubMed Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5.CrossRefPubMed
7.
Zurück zum Zitat Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, et al. NAFLD/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest. 2018;41(5):509–21.CrossRefPubMed Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, et al. NAFLD/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest. 2018;41(5):509–21.CrossRefPubMed
9.
Zurück zum Zitat Eslam M, Sarin SK, Wong VWS, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919.CrossRefPubMed Eslam M, Sarin SK, Wong VWS, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919.CrossRefPubMed
10.
Zurück zum Zitat Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 2021;73:1194–8.CrossRefPubMed Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 2021;73:1194–8.CrossRefPubMed
11.
Zurück zum Zitat Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, et al. The times they are a‑changin’ (for NAFLD as well). J Hepatol. 2020;73:1307–9.CrossRefPubMed Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, et al. The times they are a‑changin’ (for NAFLD as well). J Hepatol. 2020;73:1307–9.CrossRefPubMed
12.
Zurück zum Zitat Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 Jun 20:S0168–8278(23)00418‑X. . Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 Jun 20:S0168–8278(23)00418‑X. .
13.
Zurück zum Zitat Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;17. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;17.
14.
Zurück zum Zitat Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61. Sep.CrossRefPubMed Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61. Sep.CrossRefPubMed
15.
Zurück zum Zitat Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–22. Jul.CrossRefPubMedPubMedCentral Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–22. Jul.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jakicic JM, Rogers RJ, Davis KK, Collins KA. Role of Physical Activity and Exercise in Treating Patients with Overweight and Obesity. Clin Chem. 2018;64(1):99–107. Jan.CrossRefPubMed Jakicic JM, Rogers RJ, Davis KK, Collins KA. Role of Physical Activity and Exercise in Treating Patients with Overweight and Obesity. Clin Chem. 2018;64(1):99–107. Jan.CrossRefPubMed
17.
Zurück zum Zitat Kanaley JA, Colberg SR, Corcoran MH, Malin SK, Rodriguez NR, Crespo CJ, et al. Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2022;1;54(2):353–68. Feb.CrossRef Kanaley JA, Colberg SR, Corcoran MH, Malin SK, Rodriguez NR, Crespo CJ, et al. Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2022;1;54(2):353–68. Feb.CrossRef
18.
Zurück zum Zitat Tucker WJ, Fegers-Wustrow I, Halle M, Haykowsky MJ, Chung EH, Kovacic JC. Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4. J Am Coll Cardiol. 2022 Sep 13;80(11):1091–1106. Tucker WJ, Fegers-Wustrow I, Halle M, Haykowsky MJ, Chung EH, Kovacic JC. Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4. J Am Coll Cardiol. 2022 Sep 13;80(11):1091–1106.
19.
Zurück zum Zitat Smith PJ, Merwin RM. The Role of Exercise in Management of Mental Health Disorders: An Integrative Review. Annu Rev Med. 2021;27;72:45–62. Jan.CrossRef Smith PJ, Merwin RM. The Role of Exercise in Management of Mental Health Disorders: An Integrative Review. Annu Rev Med. 2021;27;72:45–62. Jan.CrossRef
20.
Zurück zum Zitat Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;9;313(22):2263–73. Jun.CrossRef Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;9;313(22):2263–73. Jun.CrossRef
21.
Zurück zum Zitat Wang X, Wang A, Zhang R, Cheng S, Pang Y. Associations between Healthy Lifestyle and All-Cause Mortality in Individuals with Metabolic Associated Fatty Liver Disease. Nutrients. 2022;11;14(20):4222. Oct.CrossRef Wang X, Wang A, Zhang R, Cheng S, Pang Y. Associations between Healthy Lifestyle and All-Cause Mortality in Individuals with Metabolic Associated Fatty Liver Disease. Nutrients. 2022;11;14(20):4222. Oct.CrossRef
22.
Zurück zum Zitat Chun HS, Lee M, Lee HA, Oh SY, Baek HJ, Moon JW, et al. Association of Physical Activity With Risk of LF, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023;21(2):358–369.e1. 2.CrossRefPubMed Chun HS, Lee M, Lee HA, Oh SY, Baek HJ, Moon JW, et al. Association of Physical Activity With Risk of LF, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023;21(2):358–369.e1. 2.CrossRefPubMed
23.
Zurück zum Zitat Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(5):1264–1281.e4.CrossRefPubMed Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(5):1264–1281.e4.CrossRefPubMed
24.
Zurück zum Zitat Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J Phys Act Health. 2009;6(6):790–804. Nov.CrossRefPubMed Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J Phys Act Health. 2009;6(6):790–804. Nov.CrossRefPubMed
25.
Zurück zum Zitat Divney AA, Murillo R, Rodriguez F, Mirzayi CA, Tsui EK, Echeverria SE. Diabetes Prevalence by Leisure‑, Transportation-, and Occupation-Based Physical Activity Among Racially/Ethnically Diverse U.S. Adults. Diabetes Care. 2019;42(7):1241–7. Jul.CrossRefPubMedPubMedCentral Divney AA, Murillo R, Rodriguez F, Mirzayi CA, Tsui EK, Echeverria SE. Diabetes Prevalence by Leisure‑, Transportation-, and Occupation-Based Physical Activity Among Racially/Ethnically Diverse U.S. Adults. Diabetes Care. 2019;42(7):1241–7. Jul.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Chu NM, Hong J, Harasemiw O, Chen X, Fowler KJ, al Dasgupta I. Global Renal Exercise Network. Chronic kidney disease, physical activity and cognitive function in older adults-results from the National Health and Nutrition Examination Survey (2011–2014). Nephrol Dial Transplant. 2022;19;37(11):2180–9. Oct.CrossRef Chu NM, Hong J, Harasemiw O, Chen X, Fowler KJ, al Dasgupta I. Global Renal Exercise Network. Chronic kidney disease, physical activity and cognitive function in older adults-results from the National Health and Nutrition Examination Survey (2011–2014). Nephrol Dial Transplant. 2022;19;37(11):2180–9. Oct.CrossRef
28.
Zurück zum Zitat American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):14–S31.CrossRef American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):14–S31.CrossRef
29.
Zurück zum Zitat Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30.CrossRefPubMed Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30.CrossRefPubMed
30.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.CrossRefPubMed
31.
Zurück zum Zitat Centers for Disease Control. Prevention . Testing for HCV infection: an update of guidance for clinicians and laboratorians. Mmwr Morb Mortal Wkly Rep. 2013;62:362–5. Centers for Disease Control. Prevention . Testing for HCV infection: an update of guidance for clinicians and laboratorians. Mmwr Morb Mortal Wkly Rep. 2013;62:362–5.
32.
Zurück zum Zitat Coffin CS, Zhou K, Terrault NA. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology. 2019;156(e3):355–68.CrossRefPubMed Coffin CS, Zhou K, Terrault NA. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology. 2019;156(e3):355–68.CrossRefPubMed
33.
Zurück zum Zitat Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008;48(4):606–13. Apr.CrossRefPubMed Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008;48(4):606–13. Apr.CrossRefPubMed
34.
Zurück zum Zitat Yang C, Jia X, Wang Y, Fan J, Zhao C, Yang Y, et al. Trends and influence factors in the prevalence, intervention, and control of metabolic syndrome among US adults, 1999–2018. BMC Geriatr. 2022;19;22(1):979. Dec.CrossRef Yang C, Jia X, Wang Y, Fan J, Zhao C, Yang Y, et al. Trends and influence factors in the prevalence, intervention, and control of metabolic syndrome among US adults, 1999–2018. BMC Geriatr. 2022;19;22(1):979. Dec.CrossRef
35.
Zurück zum Zitat Guerra JVS, Dias MMG, Brilhante AJVC, Terra MF, García-Arévalo M, Figueira ACM. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients. 2021;18;13(8):2830. Aug.CrossRef Guerra JVS, Dias MMG, Brilhante AJVC, Terra MF, García-Arévalo M, Figueira ACM. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients. 2021;18;13(8):2830. Aug.CrossRef
36.
Zurück zum Zitat El-Agroudy NN, Kurzbach A, Rodionov RN, O’Sullivan J, Roden M, Birkenfeld AL. Are Lifestyle Therapies Effective for NAFLD Treatment? Trends Endocrinol Metab. 2019;30(10):701–9. Oct.CrossRefPubMed El-Agroudy NN, Kurzbach A, Rodionov RN, O’Sullivan J, Roden M, Birkenfeld AL. Are Lifestyle Therapies Effective for NAFLD Treatment? Trends Endocrinol Metab. 2019;30(10):701–9. Oct.CrossRefPubMed
37.
Zurück zum Zitat Shojaee-Moradie F, Cuthbertson DJ, Barrett M, Jackson NC, Herring R, Thomas EL, et al. Exercise training reduces liver fat and increases rates of VLDL clearance but not VLDL production in NAFLD. J Clin Endocrinol Metab. 2016;101(11):4219–28.CrossRefPubMed Shojaee-Moradie F, Cuthbertson DJ, Barrett M, Jackson NC, Herring R, Thomas EL, et al. Exercise training reduces liver fat and increases rates of VLDL clearance but not VLDL production in NAFLD. J Clin Endocrinol Metab. 2016;101(11):4219–28.CrossRefPubMed
38.
Zurück zum Zitat Martins C, Morgan L, Truby H. A review of the effects of exercise on appetite regulation: an obesity perspective. Int J Obes (2005). 2008;32(9):1337–1347. Martins C, Morgan L, Truby H. A review of the effects of exercise on appetite regulation: an obesity perspective. Int J Obes (2005). 2008;32(9):1337–1347.
39.
Zurück zum Zitat Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008–2011). J Hepatol. 2015;63(2):486–93.CrossRefPubMed Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008–2011). J Hepatol. 2015;63(2):486–93.CrossRefPubMed
40.
Zurück zum Zitat Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66(1):123–31.CrossRefPubMed Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66(1):123–31.CrossRefPubMed
41.
Zurück zum Zitat Longo M, Meroni M, Paolini E, Macchi C, Dongiovanni P. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? Metabolism. 2021;117:154708.CrossRefPubMed Longo M, Meroni M, Paolini E, Macchi C, Dongiovanni P. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending? Metabolism. 2021;117:154708.CrossRefPubMed
42.
Zurück zum Zitat Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, et al. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. Cancers (basel). 2020;29;12(6):1407. May.CrossRef Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, et al. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. Cancers (basel). 2020;29;12(6):1407. May.CrossRef
43.
Zurück zum Zitat Saran U, Guarino M, Rodríguez S, Simillion C, Montani M, Foti M, et al. Anti-tumoral effects of exercise on hepatocellular carcinoma growth. Hepatol Commun. 2018;22;2(5):607–20. Mar.CrossRef Saran U, Guarino M, Rodríguez S, Simillion C, Montani M, Foti M, et al. Anti-tumoral effects of exercise on hepatocellular carcinoma growth. Hepatol Commun. 2018;22;2(5):607–20. Mar.CrossRef
44.
Zurück zum Zitat Hamer M, Sabia S, Batty GD, Shipley MJ, Tabák AG, Singh-Manoux A, et al. Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Circulation. 2012;21;126(8):928–33. Aug.CrossRef Hamer M, Sabia S, Batty GD, Shipley MJ, Tabák AG, Singh-Manoux A, et al. Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Circulation. 2012;21;126(8):928–33. Aug.CrossRef
45.
Zurück zum Zitat Li H, Wu X, Bai Y, Wei W, Li G, Fu M, et al. Physical activity attenuates the associations of systemic immune-inflammation index with total and cause-specific mortality among middle-aged and older populations. Sci Rep. 2021;15;11(1):12532. Jun.CrossRef Li H, Wu X, Bai Y, Wei W, Li G, Fu M, et al. Physical activity attenuates the associations of systemic immune-inflammation index with total and cause-specific mortality among middle-aged and older populations. Sci Rep. 2021;15;11(1):12532. Jun.CrossRef
46.
Zurück zum Zitat Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;21;380(9838):219–29. Jul.CrossRef Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;21;380(9838):219–29. Jul.CrossRef
Metadaten
Titel
Association of physical activity with MAFLD/MASLD and LF among adults in NHANES, 2017–2020
verfasst von
Minhua Li
Publikationsdatum
03.01.2024
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-023-02314-0